Gentian Diagnostics ASA (OSL:GENT)
Norway · Delayed Price · Currency is NOK 39.70
+1.40 (3.66%)
Nov 2, 2026, 4:25 PM CET
Gentian Diagnostics ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 191.35 | 176.5 | 152.07 | 135.15 | 101.64 | 83.12 |
Other Revenue | - | - | - | - | 10.29 | 16.89 |
| 191.35 | 176.5 | 152.07 | 135.15 | 111.92 | 100.01 | |
Revenue Growth | 10.92% | 16.06% | 12.52% | 20.76% | 11.91% | 26.78% |
Cost of Revenue | 82.71 | 78.3 | 69.25 | 70.91 | 52.64 | 43.18 |
Gross Profit | 108.65 | 98.2 | 82.82 | 64.25 | 59.29 | 56.83 |
Selling, General & Admin | 54.72 | 54.33 | 49.78 | 48.12 | 37.42 | 34.35 |
Research & Development | 31.1 | 23.16 | 21.92 | 36.08 | - | - |
Other Operating Expenses | -5.32 | -4.75 | -4.6 | -7.19 | 34.86 | 37.98 |
Operating Expenses | 80.5 | 72.75 | 67.09 | 77.01 | 82.52 | 79.68 |
Operating Income | 28.15 | 25.45 | 15.72 | -12.76 | -23.23 | -22.85 |
Interest Expense | -1.24 | -0.67 | -0.66 | -0.8 | -1.26 | -1.38 |
Interest & Investment Income | 4.17 | 3.5 | 3.59 | 2.67 | 1.11 | 0.09 |
Currency Exchange Gain (Loss) | -2.63 | -2.63 | 1.5 | 0.6 | -0.2 | -0.6 |
Other Non Operating Income (Expenses) | 0.02 | 0.02 | -0.08 | -0.08 | -0.05 | -0.06 |
EBT Excluding Unusual Items | 28.47 | 25.67 | 20.06 | -10.37 | -23.62 | -24.79 |
Asset Writedown | -30.24 | - | - | - | - | - |
Pretax Income | -1.78 | 25.67 | 20.06 | -10.37 | -23.62 | -24.79 |
Income Tax Expense | 3.28 | 12.41 | -25.23 | 0.28 | - | - |
Net Income | -5.06 | 13.26 | 45.29 | -10.65 | -23.62 | -24.79 |
Net Income to Common | -5.06 | 13.26 | 45.29 | -10.65 | -23.62 | -24.79 |
Net Income Growth | - | -70.73% | - | - | - | - |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 16 | 15 | 15 | 15 |
Shares Change | -0.46% | -1.73% | 2.21% | - | 0.04% | 0.07% |
EPS (Basic) | -0.33 | 0.86 | 2.94 | -0.69 | -1.53 | -1.61 |
EPS (Diluted) | -0.33 | 0.86 | 2.87 | -0.69 | -1.53 | -1.61 |
EPS Growth | - | -70.05% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 22.1 | 41.38 | 12.08 | 14.5 | -22.59 | -28.08 |
Free Cash Flow Per Share | 1.43 | 2.67 | 0.77 | 0.94 | -1.47 | -1.82 |
Dividend Per Share | 0.600 | 0.600 | 0.400 | - | - | - |
Dividend Growth | 50.00% | 50.00% | - | - | - | - |
Gross Margin | 56.78% | 55.64% | 54.46% | 47.54% | 52.97% | 56.83% |
Operating Margin | 14.71% | 14.42% | 10.34% | -9.44% | -20.76% | -22.84% |
Profit Margin | -2.64% | 7.51% | 29.79% | -7.88% | -21.10% | -24.79% |
Free Cash Flow Margin | 11.55% | 23.45% | 7.94% | 10.73% | -20.18% | -28.07% |
EBITDA | 31.13 | 28.52 | 18.6 | -9.9 | -20.49 | -21.32 |
EBITDA Margin | 16.27% | 16.16% | 12.23% | -7.32% | -18.30% | -21.32% |
D&A For EBITDA | 2.98 | 3.07 | 2.88 | 2.87 | 2.75 | 1.53 |
EBIT | 28.15 | 25.45 | 15.72 | -12.76 | -23.23 | -22.85 |
EBIT Margin | 14.71% | 14.42% | 10.34% | -9.44% | -20.76% | -22.84% |
Effective Tax Rate | - | 48.35% | - | - | - | - |
Revenue as Reported | - | - | - | - | 111.92 | 100.01 |